A method to selectively kill glucose-sensitive cancer cells via modulation of Calcium-signaling upon inhibition of glucose import. One of the hallmarks of cancer is their increased uptake and dependence on glucose, rendering them sensitive to glucose deprivation. This technology exclusively targets glucose-sensitive cancer cells such as those present in glioblastoma, osteosarcoma and adenosarcoma and would be a useful asset for pharmaceutical companies in the oncology space.
A combination of Glucose transporter (GLUT) inhibitors and an inhibitor of intracellular Calcium-ATPases are necessary to achieve selective killing of glucose sensitive cancer cells. GLUT inhibitors such as the GLUT1 inhibitor, STF-31, and the GLUT4 inhibitor, Ritonavir, when combined with Calcium-ATPase inhibitors such as thapsigargin and 2-APB produce a synergistic cell killing effect on glucose sensitive cancer cell lines such as those derived from glioblastoma, osteosarcoma and adenosarcoma. s achieved by the use of glucose transporter inhibitors such as the GLUT 1 kill cancer cells.
As a combination therapeutic comprising off-patent GLUT inhibitors and intracellular inhibitors of Calcium-ATPases may be attractive to pharma companies in the oncology space.
This strategy was found to be selective in killing glucose-sensitive cancer cells and did not cause any cell death in normal cells.